Using mRNA technology to develop a treatment for respiratory viruses
mRNA-encoded Cas13 as a pan-respiratory antiviral
This study is exploring a new way to treat respiratory viruses, like RSV, flu, and COVID-19, using a special tool that targets and breaks down the virus's genetic material, aiming to create a safer and more effective treatment for everyone dealing with these infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11004159 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating respiratory viruses by utilizing mRNA-encoded Cas13, a programmable enzyme that can target and degrade viral RNA. The study aims to create a pan-respiratory antiviral treatment that can effectively combat multiple viruses, including RSV, influenza, and SARS-CoV-2. By using synthetic mRNA for delivery, the researchers hope to achieve a safer and more efficient method of treatment compared to traditional antiviral drugs. This innovative strategy could lead to a significant advancement in how respiratory viral infections are managed.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals at high risk for severe respiratory infections, such as those with underlying health conditions or compromised immune systems.
Not a fit: Patients who are not affected by respiratory viral infections or those who do not meet the eligibility criteria for the treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option for patients suffering from various respiratory viral infections.
How similar studies have performed: Other research has shown promising results with mRNA technology in vaccine development, indicating potential for success in antiviral applications as well.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Santangelo, Philip J — Emory University
- Study coordinator: Santangelo, Philip J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.